A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC)
Alberto Chiappori(Moffitt Cancer Center), M. S. Berger(Duke University), Johnetta Blakely(Campbell Clinic), M. M. Modiano(Georgetown University), Ravi Salgia(City Of Hope National Medical Center), Simran Malik(Washington University in St. Louis), M. Moezi, J. Stephenson(Georgetown University), Quincy S. Chu, Marshall T. Schreeder(Clearview Cancer Institute)
Cited by 11
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
|Journal for ImmunoTherapy of Cancer|2018|1.3k